Form 4: Oncology Institute Director Acquires 50,000 Shares of Restricted Stock

Mark L. Pacala, a director at Oncology Institute, acquired 50,000 shares of restricted stock on November 22, 2024, which will vest at the 2025 annual shareholder meeting.

Summary

• Mark L. Pacala, a director at Oncology Institute, acquired 50,000 shares of common stock on November 22, 2024.
• These shares were granted as restricted stock units.
• The restricted stock units will vest in full at the company's 2025 annual shareholder meeting.
• Vesting is contingent upon Mr. Pacala's continued service with the company through the vesting date.
• Following this transaction, Mr. Pacala beneficially owns 134,409 shares of Oncology Institute stock.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a director's increased stake in the company, aligning their interests with shareholders. It is a routine transaction, so the sentiment is not extremely high.

Positives

• The acquisition of restricted stock by a director signals confidence in the company's future.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Risks

• The vesting of the restricted stock is contingent on continued service, which could be a risk if the director were to leave the company before the vesting date.

Future Outlook

The restricted stock units will vest at the 2025 annual shareholder meeting, subject to continued service.

Industry Context

This is a standard practice for incentivizing and aligning the interests of company directors with the long-term performance of the company, particularly in the biotech and healthcare sectors.

Comparison to Industry Standards

• The use of restricted stock units as compensation for directors is a common practice across various industries, including biotech and healthcare.
• Many companies use similar vesting schedules tied to annual shareholder meetings or specific performance milestones.
• The amount of stock granted is within the typical range for director compensation packages in comparable companies.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment to the company's long-term success.
• Employees may see this as a sign of stability and confidence in the company's future.

Next Steps

• The restricted stock units will vest at the 2025 annual shareholder meeting if the director continues to serve the company.

Key Dates

Keywords

restricted stock, share acquisition, insider trading, beneficial ownership, Oncology Institute, director, stock units, vesting